Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Ideaya Biosciences Inc (NASDAQ: IDYA) was $37.03 for the day, up 5.53% from the previous closing price of $35.09. In other words, the price has increased by $5.53 from its previous closing price. On the day, 1.54 million shares were traded. IDYA stock price reached its highest trading level at $37.8 during the session, while it also had its lowest trading level at $34.75.
Ratios:
Our analysis of IDYA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.44 and its Current Ratio is at 12.44. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
On September 18, 2025, Guggenheim started tracking the stock assigning a Buy rating and target price of $50.Guggenheim initiated its Buy rating on September 18, 2025, with a $50 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IDYA now has a Market Capitalization of 3246287104 and an Enterprise Value of 2486638080. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.11 while its Price-to-Book (P/B) ratio in mrq is 2.97. Its current Enterprise Value per Revenue stands at 11.575 whereas that against EBITDA is -12.052.
Stock Price History:
The Beta on a monthly basis for IDYA is 0.10, which has changed by 0.5444542 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, IDYA has reached a high of $39.28, while it has fallen to a 52-week low of $13.45. The 50-Day Moving Average of the stock is 8.69%, while the 200-Day Moving Average is calculated to be 44.65%.
Shares Statistics:
IDYA traded an average of 1.04M shares per day over the past three months and 946220 shares per day over the past ten days. A total of 87.67M shares are outstanding, with a floating share count of 83.79M. Insiders hold about 4.42% of the company’s shares, while institutions hold 103.21% stake in the company. Shares short for IDYA as of 1767139200 were 8247135 with a Short Ratio of 7.93, compared to 1764288000 on 7717025. Therefore, it implies a Short% of Shares Outstanding of 8247135 and a Short% of Float of 11.1.
Earnings Estimates
. The current market rating for Ideaya Biosciences Inc (IDYA) reflects the collective analysis of 17.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.74 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$0.75 and -$1.48 for the fiscal current year, implying an average EPS of -$1.25. EPS for the following year is -$3.56, with 17.0 analysts recommending between -$2.31 and -$4.63.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 17 analysts. It ranges from a high estimate of $22.2M to a low estimate of -$1.6M. As of. The current estimate, Ideaya Biosciences Inc’s year-ago sales were $7M
A total of 18 analysts have provided revenue estimates for IDYA’s current fiscal year. The highest revenue estimate was $275M, while the lowest revenue estimate was $207.8M, resulting in an average revenue estimate of $217.27M. In the same quarter a year ago, actual revenue was $7M
